Optimization to detect TP53 mutations in circulating cell-free tumor DNA from patients with serous epithelial ovarian cancer

Obstetrics & Gynecology Science
Yu Ran ParkYoung-Tak Kim

Abstract

Circulating cell-free tumor DNA (cfDNA) is the DNA released by apoptotic and necrotic cells of the primary tumor into the blood during the period of tumor development. The cfDNA reflects the genetic and epigenetic alterations of the original tumor. TP53 mutations are a defining feature of high-grade serous ovarian carcinoma. We optimized the methods for detecting TP53 mutations in cfDNA from blood samples. We confirmed the correlation of TP53 mutation in primary ovarian cancer tissue and it in cfDNA using digital polymerase chain reaction (dPCR). We found 12 frequent mutation sites in TP53 using The Cancer Genome Atlas and Catalogue of Somatic Mutations in Cancer data and manufactured 12 primers. The mutations in tissues were evaluated in fresh-frozen tissue (FFT) and formalin-fixed paraffin-embedded tissue (FFPET). We performed a prospective analysis of serial plasma samples collected from 4 patients before debulking surgery. We extracted cfDNA and calculated its concentration in blood. dPCR was used to analyze TP53 mutations in cfDNA, and we compared TP53 mutations in ovarian cancer tissue with those in cfDNA. Ten primers out of 12 detected the presence of TP53 mutations in FFT, FFPET, and cfDNA. In FFT and FFPET tissue, ther...Continue Reading

References

Jan 2, 2003·Nature Reviews. Cancer·Julian Downward
Sep 25, 2009·Nature Reviews. Cancer·Arnold J Levine, Moshe Oren
Jan 6, 2010·Molecular and Cellular Biochemistry·Rosa Estela Caseira CabralMaria da Gloria Costa Carvalho
Aug 18, 2010·International Journal of Cancer. Journal International Du Cancer·Pauline WimbergerHeidi Schwarzenbach
Jul 2, 2011·Nature·UNKNOWN Cancer Genome Atlas Research Network
Nov 1, 2011·Analytical Chemistry·Benjamin J HindsonBill W Colston
Mar 15, 2013·The New England Journal of Medicine·Sarah-Jane DawsonNitzan Rosenfeld
Jan 23, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Luis A Diaz, Alberto Bardelli
Apr 2, 2014·Nature Reviews. Clinical Oncology·Richard L Schilsky
Jan 21, 2016·Oncology Letters·Xuefeng ShaoShaoqing Ju

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
biopsy

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Related Papers

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
Fangfei GaoFrank McCaughan
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B
A H ReidT J O'Leary
Cancer Biomarkers : Section a of Disease Markers
Agnieszka M MazurekE Małusecka
© 2022 Meta ULC. All rights reserved